A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment
A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment
复制标题
DOI：
10.1136/ard.2003.012914
复制
发表时间：
2004-09-01
影响因子：
27.4
通讯作者：
Houssiau, FA
中科院分区：
文献类型：
--
作者：
Durez, P;Toukap, AN;Houssiau, FA
目的：比较静脉（IV）冲击甲基强的松龙（MP）和英夫利昔单抗（IFX）对接受甲氨蝶呤（MTX）治疗的严重活动性类风湿性关节炎（RA）患者的短期临床和生物学效应。方法：尽管接受甲氨蝶呤（MTX）治疗但仍患有活动性 RA 的患者被随机分配接受单次静脉输注 MP（1 g）或 3 次静脉输注 IFX（3 mg/kg），分别在第 0、2 和 6 周。对患者的疾病活动指标进行“盲目”评估。通过 SF-36 健康调查评估生活质量 (QoL)。在基线、第 2 周和第 6 周测量血清基质金属蛋白酶 3 (MMP-3) 滴度。结果：与基线相比，仅 IFX 组的所有活动指标，包括血清 C 反应蛋白 (CRP) 滴度都有显着改善。在第 14 周、第 6/9 周 (67%) 和4/9 (44%) IFX 患者符合 ACR20 和 50 缓解标准，而只有 1/12 (8%) 和 0/12 (0%) MP 患者符合这种情况 (p
Objectives: To compare the short term clinical and biological effects of intravenous (IV) pulse methylprednisolone (MP) and infliximab (IFX) in patients with severe active rheumatoid arthritis (RA) despite methotrexate (MTX) treatment.Methods: Patients with active RA despite MTX treatment were randomly allocated to receive a single IV infusion of MP (1 g) or three IV infusions of IFX (3 mg/kg) on weeks 0, 2, and 6. Patients were "blindly'' evaluated for disease activity measures. Quality of life (QoL) was evaluated through the SF-36 health survey. Serum matrix metalloproteinase-3 (MMP-3) titres were measured at baseline, weeks 2 and 6.Results: Compared with baseline, significant improvement was noted in all activity measures, including serum C reactive protein (CRP) titres, in the IFX group only. At week 14, 6/9 (67%) and 4/9 (44%) IFX patients met the ACR20 and 50 response criteria, while this was the case in only 1/12 (8%) and 0/12 (0%) MP patients, respectively (p